Zoetis (ZTS) Wins FDA Approval For Convenia RTU, Is It Still Below Fair Value?

Why the new Convenia approval matters for Zoetis

Zoetis (ZTS) just received FDA approval for Convenia RTU for Dogs, a single dose injectable antibiotic that covers up to 14 days of treatment for susceptible canine skin infections.

This new formulation builds on the existing Convenia franchise and is aimed at veterinarians treating dogs of all sizes, particularly medium to large breeds where smaller volume injections can be easier to administer.

The Convenia RTU news lands at a sensitive moment for Zoetis shareholders, with the stock at US$83.18 and strong short term momentum. The 30 day share price return of 19.36% and 90 day gain of 9.39% sit against a year to date share price decline of 33.94% and a 1 year total shareholder return that is down 41.08%. This points to a rebound in recent weeks but a still weak multi year experience for long term holders.

Scan beyond Zoetis and this antibiotic approval by checking a curated 33 healthcare AI stocks that could benefit as pet care and veterinary services increasingly focus on data and diagnostics.

Zoetis has snapped back in the last month after a much tougher 1 and 5 year stretch. After that kind of whiplash, does the current valuation still leave enough on the table for new buyers, or has most of the easy upside already been claimed?

Most Popular Narrative: 10% Undervalued

Against Zoetis' last close at $83.18, the most followed narrative pegs fair value at $92.92, creating a valuation gap that has investors weighing a solid animal health franchise against slower growth and balance sheet questions.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I’m not sure how much of this could be attributable to the 11% YoY decline in Pet segment revenues, but this is just something to watch out for if you’re interested in investing in the business.

See why 29 investors see Zoetis as 10% undervalued.

According to ValueInvestingSubstack, that fair value of $92.92 is built using a discount rate of 7.108%, a long run revenue growth rate of 4.06% and a profit margin assumption of 28.03%. The end result is a view that Zoetis is about 10.5% undervalued, which is a more modest gap than the 56.4% intrinsic discount implied by the SWS DCF model that prices future cash flows at $190.68 per share.

The narrative leans heavily on Zoetis' position as a large animal health specialist with $9,525.0m in annual revenue and $2,637.0m in net income. It highlights that earnings expanded by 6.9% per year over the last 5 years and 1.8% over the past 12 months, comfortably above the 1% sector earnings growth but slower than the 6.9% multi year pace.

Debt funded capital returns sit at the center of the debate. The author points out that total borrowings rose to roughly $9b, with management using convertible debt to support buybacks at the same time as total shareholder payouts exceeded free cash flow. That capital structure choice helps explain why reported return on equity is very high at 83.77%, yet is described as skewed by leverage and backed by liabilities that are entirely from higher risk funding sources rather than customer deposits.

On pricing, the narrative flags Zoetis as "the Pfizer of animal health" that can raise prices through a fragmented vet clinic network. Internal work cited in the piece references roughly 5% annual revenue growth made up of about 4% pricing and 1% volume, compared against a reported 1.9% forecast revenue growth rate going forward in the SWS dataset. That slower top line outlook, alongside earnings expected to expand 2.6% per year versus 16.9% for the wider US market, feeds into why the narrative sees value here without framing the business as a high growth story.

Product and customer concentration also feature. Around 40% of revenue coming from the top 5 product lines, roughly 60% from the top 10, and a single customer at 15% of sales between 2023 and 2025 makes Zoetis top heavy. The author treats that structure as a mixed blessing, since concentration can support scale benefits in core franchises yet leaves the group more exposed if a key therapy or channel partner underperforms.

The recent weakness in the US Companion Animal segment is the immediate pressure point. An 11% decline in that division coincided with a sharp fall in the share price earlier in 2026 and helps explain why 1 and 5 year total returns, at down 46.66% and down 59.38% respectively, lag both the US pharmaceuticals industry and the broader market over 12 months. At the same time, net profit margins have edged up from 27.6% to 27.7%, earnings quality is described as high, and the company continues to pay a 2.55% dividend, which together support the case for a still resilient profit engine.

For readers trying to square the 13x P/E, narrative fair value and recent price slide, the key takeaway in this most followed storyline is that Zoetis is treated as a steady, concentrated cash generator with meaningful debt and modest growth, rather than a broken business. That is what underpins the conclusion that the current share price offers a discount to a $92.92 fair value, but not a distressed level.

Result: Fair Value of $92.92 (UNDERVALUED)

Still, Zoetis faces two clear swing factors: a prolonged 11% slide in US Companion Animal demand and any sharper push from generics into key franchises.

Find out about the key risks to this Zoetis narrative.

Next Steps

Mixed messages on Zoetis can be confusing, so use the numbers, risks and potential rewards to pressure test your own thesis while the debate is fresh. To see that balance clearly, review the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zoetis?

If Zoetis has sharpened your interest in quality businesses, do not stop here while other investors scour wider markets for fresh opportunities and potential mispricing.

• Target strong yields and cash flow support by reviewing a focused group of income opportunities through the 4 dividend fortresses.
• Hunt for quality at a discount by scanning companies that combine solid fundamentals with attractive pricing using the 34 high quality undervalued stocks.
• Prioritise resilience in choppy conditions by filtering for sturdier balance sheets and dependable fundamentals through the list of solid balance sheet and fundamentals (24 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com